Erratum: Efficacy, safety and tolerability of b-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure (European Heart Journal PII: S0195-668X(04)00332-X and DOI: 10.1016/j.ehj.2004.05.022);Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure

European Heart Journal

Volumn 25, Issue 15, 2004, Pages 1300-1309

  Deedwania, Prakash C ^a   Gottlieb, Stephen ^b   Ghali, Jalal K ^c   Waagstein, Finn ^d   Wikstrand, John C M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Cardiac Centers of Louisiana   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Elderly; Heart failure; Prognosis; Tolerability; Blockade

Indexed keywords

METOPROLOL;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHOSPASM; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT;

EID: 3242889817     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.08.018     Document Type: Erratum

References (20)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001
2. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22:2001;1527-1560
3. Bonneux L., Barendregt J.J., Meeter K., et al. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am. J. Public. Health. 84:1994;20-28
4. CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Lancet 1999;353:9-13
5. Packer M, Coats AJS, Fowler MB et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med 2001;344(22):1651-58
6. Packer M, Fowler MB, Roecker EB et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-99
7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. (MERIT-HF). Lancet. 1999;353:2001-07
8. Hjalmarson Å, Goldstein S, Fagerberg B et al. for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302
9. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001;104:2996-3007
10. Gheorghiade M., Colucci W.S., Swedberg K. β -blockers in chronic heart failure Circulation. 107:2003;1570-1575
11. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology Komajda M., Follath F., Swedberg K., et al. The euroheart failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur. Heart J. 24:2003;464-474
12. Goldstein S, Fagerberg B, Hjalmarson Å et al. for the MERIT-HF Study Group. Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38:932-38
13. Ziegler M.G., Lake C.R., Kopin I.J. Plasma noradrenaline increases with age. Nature. 261:1976;333-335
14. Ng A.V., Callister R., Johnson D.G., et al. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension. 21:1993;498-503
15. White M., Leenen F.H.J. Aging and cardiovascular responsiveness to β-agonist in humans; role of changes in β-receptor responses vs baroreflex activity. Clin. Pharmacol. Ther. 56:1994;543-553
16. Xiao R.P., Lakatta E.G. Deterioration of β-adrenergic modulation of cardiovascular function with age. Ann. N.Y. Acad. Sci. 673:1992;293-310
17. Podrazik P.M., Schwartz J.B. Cardiovascular pharmacology of aging. Cardiol. Clin. 17:1999;17-34
18. Gottlieb S, Fisher ML, Kjekshus J et al. on behalf of the MERIT-HF Investigators. Tolerability of β -blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). Circulation 2002;105:1182-88
19. Hall S.A., Cigarra C.G., Marcoux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients. Cardiology. 25:1995;1154-1161
20. Califf R.M., O'Connor β-Blocker therapy for heart failure. The evidence is in, now the work begins. [Editorial] JAMA. 283:2000;1335-1337